Psychedelics, the media portrayal and large-language model evaluations
Catherine L. Clelland
BJPsych Open June 18, 2026 DOI: 10.1192/bjo.2026.12025 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Quantitative content analysis using large-language model Peer reviewed |
|---|---|
| Population | Media articles from 2000 to 2025 |
| Duration | 25 years (2000-2025) |
| Keywords | Sensationalism Politics Field mathematics Headline News media Media coverage Dynamics music Mass media Public opinion Advertising Fake news Criminology Public relations Popular media |
| Key points | Media coverage of psychedelic therapies increased dramatically, with positive sentiment peaking in 2020 and declining significantly from 2024, coinciding with the FDA's decision not to approve MDMA-assisted therapy for PTSD. |
Abstract
Psychedelics were used for centuries in healing and spiritual rituals, long before the mid-20th century when they became subjects of biomedical research. Although initial trials generated optimism, these were quickly overshadowed by sensationalist media coverage and political backlash. Following decades of inactivity, research on compounds including 3,4-methylenedioxymethamphetamine (MDMA) has resurged, along with the media attention. Investigating this growing interest, Bender et al employed a large-language model, validated against human raters, to analyse 25 years of media articles (2000-2025), quantifying trends in sentiment towards psychedelic therapies. Findings showed a dramatic increase in coverage, with positive sentiment peaking in 2020 followed by a significant decline from 2024, coinciding with the U.S. Food and Drug Administration's decision not to approve MDMA-assisted therapy for post-traumatic stress disorder, and echoing the dynamics of the 1960s. The authors emphasise that sustained progress in the field will require reliance on scientific evidence to advance therapeutic applications.
Citations in the library
Cites 10
- Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. New England Journal of Medicine November 3, 2022
- Single-Dose Psilocybin Treatment for Major Depressive Disorder JAMA August 31, 2023
- Dose-Response Study of N,N-Dimethyltryptamine in Humans Archives of General Psychiatry February 1, 1994
- Single-dose psilocybin-assisted therapy in major depressive disorder: A placebo-controlled, double-blind, randomised clinical trial. EClinicalMedicine February 1, 2023
- Preparing for the Bursting of the Psychedelic Hype Bubble. JAMA Psychiatry October 1, 2022
and 5 more in the library